Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study ...

Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla (donanemab-azbt) continued to demonstrate ...

New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...

Long-term extension data presented at the Alzheimer's Association International Conference showed amyloid plaque ...

Results from the long-term extension of the Phase III TRAILBLAZER-ALZ 2 trial (NCT04437511) showed sustained benefits with ...

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...

Blarcasemine met its primary endpoints, improving cognition and function over a four year period in early-stage Alzheimer’s ...

European regulators said that Eli Lilly’s Alzheimer’s treatment Kisunla should be approved for select patients.

Kisunla, a newly approved Alzheimer's drug in Taiwan, would not be covered by the National Health Insurance (NHI) system, ...

Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

INDIANAPOLIS, July 2, 2024 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), Eli Lilly and ...